Compounded Ketamine Safety Oversight: What to Know

Compounded ketamine, usually dispensed as a nasal spray, sublingual lozenge, or oral troche by telehealth providers, does not go through the U.S. Food and Drug Administration (FDA) approval process that standard prescription drugs require. The FDA defines compounding as the practice of combining, mixing, or altering ingredients to create a medication tailored to an individual patient, typically because no commercially manufactured version in that strength or form exists. Oversight of that process falls mainly to state boards of pharmacy, with a narrower layer of federal rules under the Drug Quality and Security Act of 2013.

That matters because ketamine itself is an FDA-approved generic anesthetic, but using it off-label for depression, often in a compounded nasal or oral form, places the product outside the review standards that apply to approved drugs. This guide explains who actually regulates compounded ketamine, where the oversight gaps are, and what to verify before starting treatment.

503A vs. 503B: The Two Types of Compounding Oversight

Federal law splits compounding pharmacies into two categories, and the category determines who is watching the process.

503A compounding pharmacies prepare medications for a specific, named patient based on an individual prescription. They are licensed and inspected primarily by their state board of pharmacy, not the FDA. Quality expectations come from United States Pharmacopeia (USP) general chapters, including USP <795> for non-sterile preparations (like oral troches) and USP <797> for sterile preparations (like injectable or nasal formulations). These chapters are widely adopted standards, but enforcement consistency varies by state.

503B outsourcing facilities can produce ketamine in bulk without a patient-specific prescription, similar to a small-scale manufacturer. They must register with the FDA, follow cGMP, and are subject to routine FDA inspection, which is a meaningfully higher bar than most 503A pharmacies face. Many telehealth ketamine companies source their nasal spray or troches from a 503B facility specifically because it allows larger production runs.

Neither pathway requires the kind of large-scale clinical trial data the FDA reviews before approving a new drug. That review step is what separates compounded ketamine from esketamine (Spravato), which went through the FDA's full approval process.

Why the Oversight Gap Creates Real Risk

Because compounded ketamine skips FDA pre-market review, several quality variables depend on the individual pharmacy rather than a verified standard. Potency can vary between batches of a compounded nasal spray or troche, which affects how much drug actually reaches the bloodstream and complicates comparisons to peak plasma concentration ketamine by route data drawn from clinical studies. Sterile compounding errors, though uncommon, have caused contamination incidents in other drug classes compounded under the same 503A framework.

There is also a monitoring gap. In-clinic ketamine, delivered by subcutaneous ketamine administration or IV, happens under direct observation, so a clinician can respond immediately to a spike in blood pressure or a dissociative reaction. Compounded ketamine dispensed for at-home use, by contrast, is often taken without anyone present who can intervene. Understanding ketamine safety broadly means recognizing that route and supervision, not just the drug itself, shape the risk profile.

Compounded Ketamine Is Not the Same as In-Clinic Generic Ketamine

It's worth separating two things that get conflated. Injectable ketamine used in a clinic for IV or IM infusions is typically the same FDA-approved generic drug used in hospital anesthesia, simply prescribed off-label for a new indication and sourced from a standard pharmaceutical distributor, not a compounding pharmacy. That generic drug went through FDA manufacturing review decades ago, even though its use for depression was never separately approved.

Compounding specifically applies when a pharmacy has to alter the commercial product, for example turning injectable ketamine into a nasal spray, a buccal ketamine administration lozenge, or an oral troche, because no manufacturer sells ketamine in those forms for psychiatric use. Routes also differ in how much drug reaches circulation; see ketamine half-life by route of administration and ketamine onset time by route of administration for how absorption and duration shift depending on the delivery method. Knowing which category a prescribed product falls into, generic injectable versus compounded at-home formulation, is a useful first question when evaluating oversight.